|
Title
|
Published
|
Price
|
|
Snapshots US Pharmaceuticals 2009
By: Snapdata International Group
Snapdata's Snapshots US Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the US pharmaceutical market and
|
more...
Search inside this report
|
11/12/2009
|
$600.00
|
|
Pharmaceutical Industry in Mexico
By: Aruvian's R'search
Over the past decade, pharmaceutical companies have pushed the scientific envelope, working at the cellular and molecular levels to dramatically advance the treatment of disease.
Mexico’s pharmaceutical policy environment is in a period of
|
more...
Search inside this report
|
11/1/2009
|
$275.00
|
|
Pharmaceuticals Industry Report
By: Plimsoll Publishing Ltd.
The Global Pharmaceuticals Industry Report Plimsoll Publishing Ltd. Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt? This report is an in-depth financial
|
more...
|
11/1/2009
|
$1,500.00
|
|
Pharmaceutical Industry in the United States - Porter’s Five Forces Strategy Analysis
By: Aruvian's R'search
Pharmaceutical is one of the most intense “Knowledge Driven” industries, which is continually in a state of dynamic transition.Diversities in life forms and diseases pose stiff challenge to the design of specific and targeted solutions.
|
more...
Search inside this report
|
11/1/2009
|
$175.00
|
|
Antipsychotics Market Forecast
By: Datamonitor
Introduction In 2008, seven major market sales of antipsychotics reached $18.2 billion. Datamonitor forecasts the market value to peak in 2011 when it will then succumb to generic erosion, particularly in the US where incursion is
|
more...
|
10/28/2009
|
$15,200.00
|
|
Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes
By: Datamonitor
Introduction Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest
|
more...
|
10/20/2009
|
$5,700.00
|
|
Prescription Drug Wholesaling in the US - Industry Risk Rating Report
By: IBISWorld
Industry Risk Ratings Synopsis This Industry Risk Ratings report from IBISWorld evaluates the inherent risks associated with the Prescription Drug Wholesaling in the US industry. Industry Risk is assumed to be 'the difficulty, or otherwise, of
|
more...
Search inside this report
|
10/17/2009
|
$825.00
|
|
Antidepressants Market Forecast
By: Datamonitor
Introduction With current blockbuster brands facing generic competition, Datamonitor forecasts the antidepressant market to decline at a compound annual growth rate of -2.0% (20082018). However, an antidepressant with a novel mechanism of action has huge commercial
|
more...
|
10/13/2009
|
$15,200.00
|
|
The US Government's Financial Support to Push Comparative Effectiveness Research
By: GlobalData
Summary GlobalData's new report - "The US Government’s Financial Support to Push Comparative Effectiveness Research", explores the US medical equipment industry and the intricacies of the economic stimulus bill. The US Congress in the early part
|
more...
|
10/12/2009
|
$500.00
|
|
Snapshots Australia Pharmaceuticals 2009
By: Snapdata International Group
Snapdata's Snapshots Australia Pharmaceuticals 2009 provides 2007 year-end market size data, with 2008 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Australian pharmaceutical market and
|
more...
Search inside this report
|
10/12/2009
|
$600.00
|
|
Snapshots Bulgaria Pharmaceuticals 2009
By: Snapdata International Group
Snapdata's Snapshots Bulgaria Pharmaceuticals 2009 provides 2007 year-end market size data, with 2008 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Bulgarian pharmaceutical market and
|
more...
Search inside this report
|
10/12/2009
|
$600.00
|
|
Snapshots France Pharmaceuticals 2009
By: Snapdata International Group
Snapdata's Snapshots France Pharmaceuticals 2009 provides 2007 year-end market size data, with 2008 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the French pharmaceutical market and
|
more...
Search inside this report
|
10/12/2009
|
$600.00
|
|
Commercial Insight: Anticonvulsants - Non-epilepsy label expansions provide blockbuster potential
By: Datamonitor
Introduction In 2008, seven major market sales of anticonvulsants reached $13.6 billion, making it one of the largest therapeutic drug classes in the Pharmaceutical sector. However, generic incursion of second generation anticonvulsants will continue to increase
|
more...
|
10/8/2009
|
$15,200.00
|
|
Global Pharmaceuticals Industry Report
By: Plimsoll Publishing Ltd.
The Global Pharmaceuticals Industry Report
Plimsoll Publishing Ltd.
Do you know....
The top 7 best trading partners in the industry?
Which company has the highest sales growth?
Which companies have the highest levels of
|
more...
|
10/8/2009
|
$1,500.00
|
|
Anticonvulsants Market Forecast
By: Datamonitor
Introduction In 2008, seven major market sales of anticonvulsants reached $13.6 billion, making it one of the largest therapeutic drug classes in the Pharmaceutical sector. However, generic incursion of second generation anticonvulsants will continue to increase
|
more...
|
10/8/2009
|
$15,200.00
|
|
Antidiabetics Market Forecast
By: Datamonitor
Introduction Datamonitor expects the antidiabetics market to reach $38 billion, across the seven major markets, by 2018. The growth will be driven by the launch of new drug classes, notably the DPP-IV inhibitors and GLP-1 agonists,
|
more...
|
10/8/2009
|
$15,200.00
|
|
Top 20 Cancer Therapy Brands Forecast
By: Datamonitor
Introduction The cancer therapies market offers a high level of commercial reward to a handful of companies including Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly. Cancer therapy sales totaled over $38 billion in the seven major
|
more...
|
10/2/2009
|
$15,200.00
|
|
The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets
By: Kalorama Information
At their most basic level, wellness programs represent an attempt to encourage good health and thereby decrease utilization of health care products and services. They have evolved out of necessity from the current U.S.
|
more...
|
10/1/2009
|
$3,995.00
|
|
The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)
By: Kalorama Information
The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness
|
more...
|
10/1/2009
|
$3,500.00
|
|
Top 20 Japanese Companies & Their Pipelines 2009
By: Canon Communications, LLC
In spite of the global economic downturn, Japanese pharmaceutical companies are realizing growth by capitalizing on M&A opportunities, predominantly through acquisition of specialty and generic pharmaceutical companies based in the United States and Asia-Pacific region.
|
more...
|
10/1/2009
|
$225.00
|
|
China Hospital Drug Utilization Volume Executive Summary 2nd Edition 2009
By: Draco Healthcare Consulting LLC
The total Chinese pharmaceutical market had reached RMB 828.36 billion (US$ 120.84 billion, at an exchange rate of US $1 = RMB 6.83) with an annual growth rate (AGR) of 26.50% in 2008. The growth
|
more...
|
10/1/2009
|
$4,400.00
|
|
Cough, Cold and Allergy (hay Fever) Remedies in Venezuela
By: Euromonitor International
Euromonitor International's Cough, Cold and Allergy Products in Venezuela report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data (2003-2008),
|
more...
Search inside this report
|
10/1/2009
|
$900.00
|
|
E7: The Outlook for Pharmaceuticals to 2012
By: Espicom Healthcare Intelligence
E7: The Outlook for Pharmaceuticals to 2012 is a new collection of management reports from Espicom Business Intelligence. Each report provides an individual and highly-detailed analysis of each market, looking at the key regulatory,
|
more...
|
9/30/2009
|
$3,790.00
|
|
The Outlook for Pharmaceuticals in Western Europe
By: Espicom Healthcare Intelligence
The countries of Western Europe represent a total market of over 365 million people and a combined GDP of US$14.4 trillion in 2007.
The 11 main Western European markets for pharmaceuticals are wealthy and
|
more...
|
9/30/2009
|
$3,790.00
|
|
The Outlook for Pharmaceuticals in South East Asia
By: Espicom Healthcare Intelligence
The eight Asian countries covered in this service represented a total market of 588 million people and a combined GDP of US$2.8 trillion in 2008
Business opportunities in Asian pharmaceutical markets are very different
|
more...
|
9/30/2009
|
$3,790.00
|
|
Title
|
Published
|
Price
|
(0 items)
